A key question concerning the etiology of the specific translocations observed in therapy related acute leukemia is why the MLL breakpoints occur in such a restricted genomic region in t-AL and neonatal acute leukemia compared to de novo AML (see Figure 4). Here, KMT2A is linked to acute leukemia.